Prof. Arndt Rolfs, MD
Chief Executive Officer
Arndt, founder of CENTOGENE, serves as CEO, bringing in extensive medical and scientific expertise. He received his approbation (German official license to practice as a doctor) for human medicine from the Universities of Mainz and Vienna in 1985, and was granted ...
a tenure track professorship for clinical neurology in 1997. He worked at the Department of Neurology and served as head of the Laboratory for Neurochemistry at the Free University of Berlin, at the Max Planck Institute for Molecular Genetics and at the psychiatric clinic of the University Hospital Rudolf-Virchow in Berlin. Since 1998 he has been the Head of the Neurobiological Research Laboratory and Vice-Director of the Neurological clinic and outpatients department at the University of Rostock. In 2008, Arndt was appointed Director of the Albrecht-Kossel-Institute for Neuroregeneration at the University of Rostock.
Arndt is a principal investigator of several international multicenter studies in the area of rare diseases, including the Sifap project (www.sifap.eu), the world's largest study in young stroke patients related to Fabry disease, several biomarker studies (e.g. BioGaucher, BioHunter, BioMorquio) and epidemiological studies in neurogenetic aetiologies. Arndt has an extensive track record in medical and scientific publications, acts as a consultant for international biotech and industrial companies, and is also a consultant for the EMA and FDA. Arndt is co-founder of the biotech companies Arcensus AG and Genebanking, and is a major shareholder of CENTOGENE.
Dirk H. Ehlers, PhD
Chief Operating Officer
Dirk serves as Chief Operating Officer and President of CENTOGENE’s Diagnostics division, responsible for the company’s global operations, including marketing and sales, processes and workflows for the entire genetic diagnostics business. In his role, Dirk also leads ...
the company’s legal and general administrative functions.
With more than 30 years of experience, Dirk most recently worked at Hill-Rom Holdings Inc., where he held the position of Senior Vice President and President of the Surgical Solutions Division and served as a member of the Group Executive Team. Under his leadership, Trumpf Medical was brought together with the previously separate businesses Aspen Surgical and Allen Medical. Previously, he served as President and CEO of Eppendorf AG for four years, where he enhanced its brand profile and developed new marketing and go-to-market strategies globally. He also led the company through major improvements of its operational set-up and CRM and service systems.
Dirk also formerly worked at Roche Diagnostics in Switzerland where he was head of its global Professional Diagnostics business and a member of the Diagnostics Executive Committee. In this role, he managed the merger of two business areas, site transfers and site closures and re-built the business headquarters after relocation. He was also responsible for redirecting strategic alliances and developing new OEM relationships. Before, Dirk held management board positions at Evotec AG and Fresenius Kabi AG and headed Olympus Optical’s European diagnostics business. Today he continues to be a board member of Protagen AG.
Dirk holds a M.Sc. in Physics from University RWTH Aachen, and received his PhD in Physics with distinction, summa cum laude, from University RWTH Aachen.
Prof. Peter Bauer, MD
Chief Genomic Officer
Peter serves as CGO, combining clinical and medical understanding in genetic testing with an excellent knowledge of the latest scientific developments, based on his extraordinary experience, especially in high-throughput genetic testing ...
... using next-generation sequencing.
Peter is passionate about turning medical questions into a complete and fast analytical process, ensuring that the medically driven result is brought back to the clinician and the patient immediately.
After studying Medicine in Freiburg and Berlin, Peter worked as a resident in Neurology at Rostock, and as a resident in Human Genetics at Tübingen since 1997. He received his board certification in Human Genetics in 2006, and heads the molecular diagnostic laboratory at the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. His experience ranges from medium- to high-throughput genetic analyses, including the application of next-generation sequencing in a clinical setting, genetic research in neurodegenerative disease and hereditary cancer. Peter has an extensive track record in medical and scientific publications, focusing on neurogenetics, oncogenetics, cardiogenetics, and sequencing technology. He is co-principal investigator in a large European consortium on rare neurodegenerative diseases, where he overlooks specifically gene panel, exome and genome sequencing (www.rd-neuromics.eu). Moreover, Peter is vice president of the German Society of Neurogenetics (DGNG).
Chief Financial Officer
Richard serves as CFO, providing international expertise in global financial topics at CENTOGENE. His experience and know-how supports CENTOGENE in its continued global growth plans. With over 25 years of experience in international leadership roles covering ...
... the full width of governance and risk concepts, his expertise, combined with his extensive change management skills, ensures the finance organization will enable the company to continue its expansive growth path.
Richard previously served as Head of Internal Audit at Holcim, a listed multinational company in Switzerland, where he was asked to lead the change of this function from a globally distributed model to a centralized, risk based, model.
From 1985 to 2013 he was active in different Audit- and Management-positions at (a.o.) KPMG, in Chicago, Frankfurt, Hong Kong and the Netherlands. During his international audit tenure, Richard was responsible for audits of a multitude of small and large (listed on various stock exchanges, including the US) clients in a wide variety of industries, including the Pharma industry. He developed a new entity on strategic alliances, where he also provided strategy consulting services, including business planning and related funding. As Partner in Charge of one of the offices, he created values-based turn-around. Subsequently, he was HR responsible in the management team for the audit practice of KPMG NL-south. This role led to a further roll out of his management development initiatives in Hong Kong, China and Germany. Furthermore, Richard was involved in IPO`s and Bond issuances on a variety of stock exchanges. He was an active public speaker during his leadership and business development regarding the role of the China Practice, both in Hong Kong-China, and in Europe – where he led the EMA China Practice.
Richard graduated as a Dutch CPA with the NBA and Tilburg University - the Netherlands, with further executive education programs at Harvard Business School, Insead (Executive MBA), IMD and IESE.
Volkmar Weckesser, PhD
Chief Information Officer
Volkmar serves as CIO, bringing with him broad experience in planning and implementing enterprise information systems, to support both distributed and centralized business operations. His vast skill and know-how supports CENTOGENE in ...
... the global development of IT-based genetic software infrastructure and the mutation data base, CentoMD®.
With over 20 years of experience in IT, management of large transformation programs, and process optimization, he ensures that IT is a key driver for the further development of CENTOGENE.
Volkmar previously served as CIO of the Gothaer Insurance Enterprise and CEO of the incorporated Gothaer Systems GmbH, where he successfully implemented a new IT-strategy, realigned their IT-architecture, and restructured the project portfolio.
From 2009 to 2013 Volkmar was Director IT at DekaBank, guiding the modernization of the IT-systems and the establishment of new IT governance in close collaboration with all parties involved.
Prior to that, he served as Director of IT/Organization at the HSH Nordbank AG. There he focused on planning and implementation of the enterprise-wide IT-strategy. He also successfully realized the consolidation of the IT systems (post-merger IT integration) at the HSH Nordbank AG.
Volkmar started his career as a management consultant for the Mitchell Madison Group and Monitor Company.
He studied techno mathematics at the University of Karlsruhe and holds a PhD in mathematics.
Chief Business Officer
Oved serves as Chief Business Officer with nearly three decades of broad commercial and development experience, focusing on orphan drugs for patients with rare genetic diseases. He has the overall responsibility for ...
... the company´s pharmaceutical industry programs, including enhancing existing partnerships and establishing new collaborations to facilitate drug development and improve treatment outcomes.
Oved joined CENTOGENE from Arrett Neuroscience where he held the position of President and Chief Operating Officer, having led the company’s strategy for developing therapies for Rett syndrome. Prior to that, he served as Vice President, Head of Commercial at Alnylam Pharmaceuticals, with a lead role in the organization’s transition from a technology- platform focus to a patient-centric drug development and pre-launch enterprise. Oved had a long tenure at Genzyme Corporation (now Sanofi Genzyme) as Vice President, Strategic Development, responsible for program management, business development, market assessment, and business planning for the rare genetic diseases franchise, and as General Manager of the Gaucher and MPS business. He is also a Founding Advisor of Splisense Therapeutics, Israel. Oved holds a M.Sc., Pharmacology, from Northeastern University, Boston, MA and a B.Sc., Pharmacy, from the Hebrew University, Jerusalem, Israel.
Sun Kim, PhD
Chief Strategy & Investor Relations Officer
Sun serves as Chief Strategy & Investor Relations Officer. With more than two decades of experience in the global pharmaceutical and biotechnology sectors, Sun will have the overall responsibility of working closely with CENTOGENE’s Executive Leadership...
... Team and the Supervisory Board to provide strategic guidance and alignment across the organization, developing scenarios and recommendations to support the Company’s short- and longer- term goals, and communicating company vision with the investment community.
Sun joins CENTOGENE from Shire Pharmaceutical, where he was Head of Corporate Strategy and also responsible for the investor relations function in the USA. Prior to Shire, he worked at Novartis for 6 years in multiple roles including Head of Strategy for Alcon Division and General Manager in Singapore. Sun also worked at Bausch & Lomb heading up its strategy function for the pharmaceutical business unit. Prior to his experience in the pharmaceutical industry, Sun spent 7 years as a Management Consultant at McKinsey & Company and A.T. Kearney.
Sun holds a PhD and MS in chemical engineering from Stanford University, and BS from Seoul National University. Sun is based in CENTOGENE’s Cambridge office.
Philip Lambert, PhD
Chief Scientific Officer
With over two decades of scientific and operational experience in the drug discovery field, Philip has the overall responsibility of driving CENTOGENE’s scientific programs to align with the needs of pharmaceutical partners. Philip joins CENTOGENE from Life Biosciences, a ...
... global company focused on extending the healthy lifespan of individuals by investigating eight biological pathways believed to increase longevity. He served as Senior Vice President of Discovery and Labs as well as Chief Operating Officer of two subsidiary companies, Selphagy Therapeutics and Spotlight Biosciences. Prior to Life Biosciences, Philip served as Scientific Partner and Head of Discovery at Charles River Laboratories, where he was responsible for establishing scientific credibility and delivering the business to client companies and venture capital firms. Philip also co-founded VivoPath, a preclinical screening company, offering clients discovery and development services for proof-of-concept testing. Moreover, Philip brings vast experience and know-how regarding scientific publications, having contributed to more than thirty publications in peer-reviewed scientific journals.
Philip holds a PhD in Neuropharmacology from Imperial College - University of London and a BSc in Pharmacology from the University of Liverpool. Philip is based in CENTOGENE’s Cambridge office.